| Primary |
| Contraception |
73.1% |
| Endometriosis |
5.5% |
| Hypertension |
3.6% |
| Fibromyalgia |
3.2% |
| Asthma |
2.0% |
| Crohn's Disease |
1.6% |
| Headache |
1.6% |
| Antiphospholipid Syndrome |
1.2% |
| Gastrooesophageal Reflux Disease |
1.2% |
| Menstrual Discomfort |
1.2% |
| Off Label Use |
1.2% |
| Back Pain |
0.8% |
| Hypothyroidism |
0.8% |
| Menstruation Irregular |
0.8% |
| Attention Deficit/hyperactivity Disorder |
0.4% |
| Blood Iron Decreased |
0.4% |
| Dysmenorrhoea |
0.4% |
| Glucose Tolerance Impaired |
0.4% |
| Menorrhagia |
0.4% |
| Migraine |
0.4% |
|
| Injection Site Reaction |
56.9% |
| Injection Site Atrophy |
6.1% |
| Unintended Pregnancy |
5.6% |
| Weight Decreased |
3.6% |
| Weight Increased |
3.6% |
| Metrorrhagia |
3.0% |
| Injection Site Necrosis |
2.5% |
| Rheumatoid Arthritis |
2.5% |
| Urticaria |
2.5% |
| Pelvic Pain |
2.0% |
| Rash |
2.0% |
| Injection Site Pain |
1.5% |
| Abdominal Wall Haematoma |
1.0% |
| Angioedema |
1.0% |
| Fat Necrosis |
1.0% |
| Injection Site Induration |
1.0% |
| Injection Site Mass |
1.0% |
| Injection Site Papule |
1.0% |
| Injection Site Warmth |
1.0% |
| Pain In Extremity |
1.0% |
|
| Secondary |
| Contraception |
67.8% |
| Fibromyalgia |
5.4% |
| Gastrooesophageal Reflux Disease |
5.4% |
| Endometriosis |
4.0% |
| Headache |
2.7% |
| Off Label Use |
2.7% |
| Back Pain |
1.3% |
| Blood Iron Decreased |
1.3% |
| Dysmenorrhoea |
1.3% |
| Menorrhagia |
1.3% |
| Menstrual Discomfort |
1.3% |
| Pain |
1.3% |
| Asthma |
0.7% |
| Hypothyroidism |
0.7% |
| Menstruation Irregular |
0.7% |
| Migraine |
0.7% |
| Neuralgia |
0.7% |
| Trigeminal Neuralgia |
0.7% |
|
| Injection Site Reaction |
53.3% |
| Unintended Pregnancy |
9.5% |
| Fat Necrosis |
7.6% |
| Weight Increased |
4.8% |
| Pelvic Pain |
3.8% |
| Weight Decreased |
3.8% |
| Drug Administered At Inappropriate Site |
1.9% |
| Injection Site Atrophy |
1.9% |
| Scar |
1.9% |
| Skin Lesion |
1.9% |
| Smear Cervix Abnormal |
1.9% |
| Amenorrhoea |
1.0% |
| Bone Density Decreased |
1.0% |
| Injection Site Haemorrhage |
1.0% |
| Injection Site Necrosis |
1.0% |
| Injection Site Streaking |
1.0% |
| Libido Decreased |
1.0% |
| Muscle Atrophy |
1.0% |
| Weight Fluctuation |
1.0% |
|
| Interacting |
| Contraception |
50.0% |
| Upper Respiratory Tract Infection |
50.0% |
|
| Unintended Pregnancy |
100.0% |
|
